These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 16005039)

  • 1. HIV-1 envelope pseudotyped viral vectors and infectious molecular clones expressing the same envelope glycoprotein have a similar neutralization phenotype, but culture in peripheral blood mononuclear cells is associated with decreased neutralization sensitivity.
    Louder MK; Sambor A; Chertova E; Hunte T; Barrett S; Ojong F; Sanders-Buell E; Zolla-Pazner S; McCutchan FE; Roser JD; Gabuzda D; Lifson JD; Mascola JR
    Virology; 2005 Sep; 339(2):226-38. PubMed ID: 16005039
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Passage of HIV-1 molecular clones into different cell lines confers differential sensitivity to neutralization.
    Zhang YJ; Fredriksson R; McKeating JA; Fenyö EM
    Virology; 1997 Nov; 238(2):254-64. PubMed ID: 9400598
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chimeric viruses expressing primary envelope glycoproteins of human immunodeficiency virus type I show increased sensitivity to neutralization by human sera.
    McKeating JA; Zhang YJ; Arnold C; Frederiksson R; Fenyö EM; Balfe P
    Virology; 1996 Jun; 220(2):450-60. PubMed ID: 8661395
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV-1 subtype A envelope variants from early in infection have variable sensitivity to neutralization and to inhibitors of viral entry.
    Blish CA; Nedellec R; Mandaliya K; Mosier DE; Overbaugh J
    AIDS; 2007 Mar; 21(6):693-702. PubMed ID: 17413690
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Escape from autologous humoral immunity of HIV-1 is not associated with a decrease in replicative capacity.
    Bunnik EM; Lobbrecht MS; van Nuenen AC; Schuitemaker H
    Virology; 2010 Feb; 397(1):224-30. PubMed ID: 19945135
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody-mediated neutralization of primary human immunodeficiency virus type 1 isolates: investigation of the mechanism of inhibition.
    Spenlehauer C; Kirn A; Aubertin AM; Moog C
    J Virol; 2001 Mar; 75(5):2235-45. PubMed ID: 11160727
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ex vivo neutralization of HIV-1 quasi-species by a broadly reactive humanized monoclonal antibody KD-247.
    Matsushita S; Takahama S; Shibata J; Kimura T; Shiozaki K; Eda Y; Koito A; Murakami T; Yoshimura K
    Hum Antibodies; 2005; 14(3-4):81-8. PubMed ID: 16720978
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Replicative function and neutralization sensitivity of envelope glycoproteins from primary and T-cell line-passaged human immunodeficiency virus type 1 isolates.
    Sullivan N; Sun Y; Li J; Hofmann W; Sodroski J
    J Virol; 1995 Jul; 69(7):4413-22. PubMed ID: 7769703
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of V2 mutations on escape from a potent neutralizing anti-V3 monoclonal antibody during in vitro selection of a primary human immunodeficiency virus type 1 isolate.
    Shibata J; Yoshimura K; Honda A; Koito A; Murakami T; Matsushita S
    J Virol; 2007 Apr; 81(8):3757-68. PubMed ID: 17251298
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inter-subtype cross-neutralizing antibodies recognize epitopes on cell-associated HIV-1 virions.
    Donners H; Davis D; Willems B; van der Groen G
    J Med Virol; 2003 Feb; 69(2):173-81. PubMed ID: 12683404
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cross-clade neutralization patterns among HIV-1 strains from the six major clades of the pandemic evaluated and compared in two different models.
    Brown BK; Wieczorek L; Sanders-Buell E; Rosa Borges A; Robb ML; Birx DL; Michael NL; McCutchan FE; Polonis VR
    Virology; 2008 Jun; 375(2):529-38. PubMed ID: 18433824
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epitopes corresponding to the envelope genetic subtype are present on the surface of free virions of HIV-1 group M primary isolates and can be detected in neutralization assays with extended incubation phases.
    Davis D; Donners H; Willems B; Vermoesen T; Heyndrickx L; Colebunders R; van der Groen G
    J Med Virol; 2003 Nov; 71(3):332-42. PubMed ID: 12966537
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual tropism of HIV-1 envelopes derived from renal tubular epithelial cells of patients with HIV-associated nephropathy.
    Zerhouni-Layachi B; Husain M; Ross MJ; Marras D; Sunamoto M; Liu X; Klotman PE; Klotman ME
    AIDS; 2006 Feb; 20(4):621-4. PubMed ID: 16470129
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neutralization and infectivity characteristics of envelope glycoproteins from human immunodeficiency virus type 1 infected donors whose sera exhibit broadly cross-reactive neutralizing activity.
    Cham F; Zhang PF; Heyndrickx L; Bouma P; Zhong P; Katinger H; Robinson J; van der Groen G; Quinnan GV
    Virology; 2006 Mar; 347(1):36-51. PubMed ID: 16378633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Envelope variants from women recently infected with clade A human immunodeficiency virus type 1 confer distinct phenotypes that are discerned by competition and neutralization experiments.
    Painter SL; Biek R; Holley DC; Poss M
    J Virol; 2003 Aug; 77(15):8448-61. PubMed ID: 12857914
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Postattachment neutralization of a primary strain of HIV type 1 in peripheral blood mononuclear cells is mediated by CD4-specific antibodies but not by a glycoprotein 120-specific antibody that gives potent standard neutralization.
    McInerney TL; Dimmock NJ
    AIDS Res Hum Retroviruses; 2001 Nov; 17(17):1645-54. PubMed ID: 11779352
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neutralizing antibodies decrease the envelope fluidity of HIV-1.
    Harada S; Monde K; Tanaka Y; Kimura T; Maeda Y; Yusa K
    Virology; 2008 Jan; 370(1):142-50. PubMed ID: 17900650
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design of immunogens that present the crown of the HIV-1 V3 loop in a conformation competent to generate 447-52D-like antibodies.
    Chakraborty K; Durani V; Miranda ER; Citron M; Liang X; Schleif W; Joyce JG; Varadarajan R
    Biochem J; 2006 Nov; 399(3):483-91. PubMed ID: 16827663
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The neutralization sensitivity of viruses representing human immunodeficiency virus type 1 variants of diverse subtypes from early in infection is dependent on producer cell, as well as characteristics of the specific antibody and envelope variant.
    Provine NM; Cortez V; Chohan V; Overbaugh J
    Virology; 2012 May; 427(1):25-33. PubMed ID: 22369748
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dominant-negative effect of hetero-oligomerization on the function of the human immunodeficiency virus type 1 envelope glycoprotein complex.
    Herrera C; Klasse PJ; Kibler CW; Michael E; Moore JP; Beddows S
    Virology; 2006 Jul; 351(1):121-32. PubMed ID: 16616288
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.